Shulman Joseph
Company insiders · Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC.
- Reported transaction lines
- 9
- Buy lines
- 0
- Sell lines
- 1
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-119
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 28126 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 9,374 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 25306 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 24,944 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 8375 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 1, 2023. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 4,188 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Stock Options (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 3984 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The stock options were granted on February 9, 2022. The options vested and became exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. | 2026-11-18 | 2026-11-20 | 1,961 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 10461 · SEC code covers open-market or private transactions · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. · The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $119.75 to $120.36 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. | 2026-11-18 | 2026-11-20 | ≈ $5,506,152.91 45,921 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 56382 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 9,374 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 47008 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 24,944 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 22064 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 4,188 shares/units | SEC 4 |
| Shulman Joseph Chief Technical Officer · RHYTHM PHARMACEUTICALS, INC. | RYTM RHYTHM PHARMACEUTICALS, INC. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 17876 · The Exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2025. | 2026-11-18 | 2026-11-20 | 1,961 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.